ASH , Lithuania Share this item Prof. Ingrid Pabinger-Fasching, MD from the Medical University of Vienna, Austria is commenting on the ITP Guidelines
Moshe Mittelman, MD, PhD; Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3) Moshe Mittelman, MD, PhD from the Tel Aviv University, Tel Aviv, Israel is commenting on the abstract: Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)Blood (2019) 134 (Supplement_1): 3740.https://doi.org/10.1182/blood-2019-130309 ASH , Latvia , Lithuania , Estonia , Albania 00:07:06
ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania 00:03:29
Sophie Servais, MD; Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study Sophie Servais, MD from the Université de Liège, Liège, Belgium is commenting on the abstract: Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective StudyBlood (2019) 134 (Supplement_1): 37.https://doi.org/10.1182/blood-2019-129992 ASH , Lithuania , Albania 00:03:30
Srdan Verstovsek, MD, PhD; Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial Srdan Verstovsek, MD, PhD from the MD Anderson Cancer Center, Houston, VS is commenting on the publication: Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response TrialBlood (2019) 134 (Supplement_1): 2947.https://doi.org/10.1182/blood-2019-128101 ASH , Lithuania , Albania 00:02:22
Tom Eyckmans, MD, PhD; ASH 2019 Highlights: Sickle Cell Disease Tom Eyckmans, MD, PhD from the Ziekenhuis Netwerk Antwerp, Antwerp, Belgium is commenting on his ASH 2019 Highlights in Sickle Cell Disease ASH , Lithuania , Albania 00:05:07
Valentina Gaidano, MD, PhD; 3942 Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia Valentina Gaidano, MD, PhD from the University of Turin, Orbassano, Italy is commenting on the abstract: Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid LeukemiaBlood (2019) 134 (Supplement_1): 3942.https://doi.org/10.1182/blood-2019-128085 ASH , Lithuania , Albania 00:03:51
